Table 1.
Baseline characteristics LirAlbu12
| Start of trial Total | Before Liraglutide | Before Placebo | P-value | |
|---|---|---|---|---|
| n | 27 | 27 | 27 | |
| Age (years) | 65.3 (7.3) | 65.3 (7.3) | 65.3 (7.3) | 1 |
| Woman | 5 (18.5%) | 5 (18.5%) | 5 (18.5%) | 1 |
| Weight (kg) | 99.5 (18.7) | 100 (18.5) | 99.5 (17.8) | 0.923 |
| Diabetes duration (years) | 14.8 (7.1) | 14.8 (7.1) | 14.8 (7.1) | 1 |
| HbA1c (mmol/mol) | 62 (10.7) | 62.6 (11.6) | 59.6 (12.1) | 0.356 |
| HbA1c (%) | 7.8 (1) | 7.9 (1.1) | 7.6 (1.1) | 0.356 |
| Total cholesterol (mmol/L) | 3.8 (0.9) | 3.8 (1) | 3.8 (0.8) | 0.886 |
| LDL (mmol/L) | 1.88 (0.59) | 1.82 (0.50) | 1.86 (0.61) | 0.768 |
| Triglyceride (mmol/L) | 2.20 (1.79) | 1.99 (1.31) | 2.26 (1.70) | 0.518 |
| Systolic blood pressure (mm Hg) | 136 (18) | 137 (16) | 133 (15) | 0.355 |
| eGFR (mL/min/1.73m2) | 75 (23) | 75 (23) | 73 (23) | 0.783 |
| UAER (mg/d) | 8 [7-13] | 9 [7-14] | 8 [7-12] | 0.967 |
Mean (SD), n (%) or median [IQR], groupwise comparison between liraglutide and placebo was carried out using chi square test for categorical variables and ANOVA for continuous variables
LDL Low-density lipoprotein, eGFR Estimated glomerular filtration rate, UAER: Urinary albumin excretion rate